• OPEN AN ACCOUNT
Indian Indices
Sensex
78,428.95 -210.08
( -0.27%)
Global Indices
Nasdaq
53,210.99 704.96
(1.34%)
Dow Jones
7,621.51 110.79
(1.48%)
Hang Seng
63,983.92 229.02
(0.36%)
Nikkei 225
10,890.39 32.69
(0.30%)
Forex
USD-INR
95.40 -0.19
(-0.20%)
EUR-INR
110.00 0.21
(0.19%)
GBP-INR
128.60 0.50
(0.39%)
JPY-INR
0.61 0.01
(2.47%)

EQUITY - MARKET SCREENER

Bhatia Communications & Retail (India) Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
540956
INE341Z01025
9.4267625
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
19.4
324.77
EPS(TTM)
Face Value()
Div & Yield %
1.19
1
0.17
 

raj industries ltd
Lupin receives EMA approval for Pediatric Indication of NaMuscla
Jul 01,2026
Lupin today announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla, supported by the Pediatric Investigation Plan (PIP). The approval includes two new dosage strengths, 62 mg and 83 mg capsules, in addition to the existing 167 mg, and the revised indications that cover symptomatic treatment of myotonia in children (6¨C11 years, weighing at least 20 kg), adolescents (12¨C17 years), and adults (¡Ý18 years) with non-dystrophic myotonic disorder.